ClinicalTrials.gg
RecruitingNCT07493512Updated Sep 15, 2026

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

A Phase 1 interventional study of Xaluritamig in Metastatic Castration-resistant Prostate Cancer (mCRPC), sponsored by Amgen. Recruiting at 14 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.

Planned enrollment
17th of 21
40 · median 64
Started
2026
the only one that year
Phase 1
9 of 23
3 open now
Registered
23rd of 23
by date

Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 9 in phase 1, and was the 23rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Amgen, or all of them as a file.
02

Study summary

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Browse trials for

Keywords

  • Xaluritamig
  • AMG 509
  • mCRPC
  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Mixed histologies (eg, adenocarcinoma with neuroendocrine component) are not permitted.
  • mCRPC with ≥ 1 lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scintigraphy imaging obtained within 28 days prior to enrollment.
  • Evidence of progressive disease, defined as 1 or more PCWG3 criteria:

    • Serum PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL.
    • Soft tissue progression defined as an increase ≥ 20% and an absolute increase of ≥ 5 mm in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-target lesions.
    • Progression of bone disease defined by the appearance of at least 2 new bone lesions(s) by bone scintigraphy (as per the 2+2 PCWG3 criteria).
  • Prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (\<50 ng/dL or \<1.7 nmol/L).
  • Prior progression on at least one androgen receptor pathway inhibitor (androgen receptor pathway inhibitor [ARPI], enzalutamide, abiraterone, apalutamide, darolutamide).
  • Prior treatment with only one taxane therapy in the mCRPC setting. Prior treatment with docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is permitted; however, participants must have also received one, and only one, taxane therapy in the mCRPC setting.

Exclusion criteria

Exclusion Criteria:

  • History of central nervous system . Note: Participants with treated, asymptomatic, and clinically stable dural metastases are eligible.
  • History of allergic reactions or acute reactions to the components of the trial therapies and their analogs. Participants with known to high-dose are also excluded.
  • History of that is expected to alter or may interfere with disease assessments. Participants with prior history of malignancy that have been adequately treated and who have been disease-free for >3 years are eligible, as are participants with adequately treated non-melanoma skin cancer or superficial bladder cancer.
  • Active disease that has required systemic treatment (except physiologic replacement therapy) within the past 2 years or any other diseases requiring therapy while on trial.
  • Known positive test for .
  • Presence or history of viral hepatitis infection.
  • Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or agent) within 28 days of first dose of trial treatment with the following exceptions:

    • Androgen-deprivation therapy with luteinizing hormone-releasing hormone/gonadotropin-releasing hormone (LHRH/GnRH) analogue (agonist/antagonist) is allowed.
    • ARPIs (enzalutamide, abiraterone, apalutamide, darolutamide) require a minimum of 2 weeks prior to the first dose of xaluritamig.
    • Prior prostate-specific membrane antigen (PSMA) radionuclide therapy cannot be given within 3 months prior to first dose of xaluritamig unless participant received \<2 cycles of therapy, in which case participant cannot have received PSMA radionuclide therapy within 35 days prior to first dose.
  • Any prior six transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted therapy.
  • Any prior cluster of differentiation 3 (CD3)-directed therapy.
  • Requirement for chronic systemic corticosteroid therapy (prednisone dose >10 mg/day or equivalent) or any other immunosuppressive therapies (including anti TNFα therapies).
  • Participation on any other xaluritamig trial, regardless of whether xaluritamig was administered.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Xaluritamig Proposed Regimen

    Participants will be dosed at the proposed regimen until disease progression or discontinuation of study treatment.

    Drug: Xaluritamig

Interventions

  • Participants will receive xaluritamig via short-term intravenous (IV) infusion.

    Also known as: AMG 509

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events

    This will include treatment-emergent adverse events, serious adverse events, treatment-related adverse events, and fatal adverse events.

    Time frame: Up to 3.6 Year

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Xaluritamig

    Time frame: Up to 1 Year

  2. Time to Cmax (tmax) of Xaluritamig

    Time frame: Up to 1 Year

  3. Accumulation Ratio (AR) Following Multiple Doses of Xaluritamig

    Time frame: Up to 1 Year

  4. Serum Concentration Before Dosing (Ctrough) of Xaluritamig

    Time frame: Up to 1 Year

  5. Area Under the Concentration-time Curve Over the Dosing Interval (AUC) of Xaluritamig

    Time frame: Up to 1 Year

  6. Objective Response (OR) per Modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to 3.6 Years

  7. Duration of Response (DOR) per Modified RECIST v1.1

    Time frame: Up to 3.6 Years

  8. Disease Control (DC) per Modified RECIST v1.1

    Time frame: Up to 3.6 Years

  9. Time to Response (TTR) per Modified RECIST v1.1

    Time frame: Up to 3.6 Years

  10. Number of Participants with a Prostate-specific Antigen (PSA) 50 Response

    Time frame: Up to 3.6 Years

  11. Number of Participants with a PSA 90 Response

    Time frame: Up to 3.6 Years

  12. Time to PSA 50 and PSA 90 Response

    Time frame: Up to 3.6 Years

  13. Duration of PSA 50 and PSA 90 Response

    Time frame: Up to 3.6 Years

  14. Time to PSA Progression

    Time frame: Up to 3.6 Years

  15. Time to First Subsequent Therapy

    Time frame: Up to 3.6 Years

  16. Radiographic Progression-free Survival (PFS) Per Prostate Cancer Working Group 3 (PCWG3)-modified RECIST 1.1

    Time frame: Up to 3.6 Years

  17. Overall Survival (OS)

    Time frame: Up to 3.6 Years

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2030, 51 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 51 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 25, 2026
StartActual
Apr 28, 2026
Primary completionEst.
Jul 30, 2030
CompletionEst.
Jul 30, 2030
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07493512
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Apr 28, 2026
Primary completion
Jul 30, 2030 (estimated)
Completion
Jul 30, 2030 (estimated)
Last update
Sep 15, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xaluritamig

Start the discussion